|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project.
|
21347282 |
2011 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Lymphocyte Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Colorectal Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients.
|
29762254 |
2018 |
|
Colorectal Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Given that a combination of genetic variants, rather than a single polymorphism, may explain better the genetic etiology of CRC, we studied the interplay between the variants within NLRC5, PD-L1 and the previously genotyped IFNGR1 and IFNGR2 variants, to evaluate their involvement in the risk of CRC development.
|
29408916 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
|
29762254 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer.
|
29408916 |
2018 |
|
Chronic Periodontitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
NLRC5 polymorphism is associated with susceptibility to chronic periodontitis.
|
28122660 |
2017 |
|
Localized periodontitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
One polymorphism, namely rs289723, in NLRC5 gene resulted associated with chronic slight and chronic localized periodontitis susceptibility, specifically A/A genotype was correlated with increased risk of disease development.
|
28122660 |
2017 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Role of NLRC5 in progression and reversal of hepatic fibrosis.
|
26806094 |
2016 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research.
|
28718425 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
|
27162338 |
2016 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.
|
30706093 |
2019 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Better awareness of the multiple roles of NLRC5 will help to define its overall contribution to immune responses and cancer.
|
28261210 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5 is an interferon γ-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival.
|
29762254 |
2018 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we review the role of NLRC5 in cancer immune evasion and the future prospects for cancer research.
|
28718425 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Better awareness of the multiple roles of NLRC5 will help to define its overall contribution to immune responses and cancer.
|
28261210 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
|
27162338 |
2016 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
NLRC5 is an interferon γ-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival.
|
29762254 |
2018 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Here, we discuss the molecular function and mechanism of CITA/NLRC5 in the MHC class I pathway and its role in cancer.
|
30706093 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Mutations affecting the HLA class I transactivator NLRC5 were observed as a potential new immune evasion mechanism in 26% (6% abrogating) of the analyzed tumors.
|
29900056 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Thus, our findings suggest that NLRC5 may play an important role in progression of HCC and provide a potential therapeutic value in this tumor.
|
26975630 |
2016 |
|
Fibrosis, Liver
|
0.040 |
Biomarker
|
disease |
BEFREE |
NLRC5, as the largest member of nucleotide-binding domain and leucine-rich repeat (NLRs) family, has recently been implicated in the development of hepatic fibrosis.
|
27525969 |
2016 |